Table 1 Demographic and clinicopathologic data of the patients with or without postoperative chemotherapy
From: Does postoperative chemotherapy improve overall survival of patients with ypT1-2N0 cancer?
Variable | All cohort | pCHT | no pCHT | P value†|
|---|---|---|---|---|
n = 134 | n = 56 | n = 78 | ||
Age (years) |  |  |  | 0.367‡ |
 Mean (SD) | 54.2 (10.8) | 53.4 (11.5) | 54.8 (10.2) |  |
Gender | Â | Â | Â | 0.519 |
 Female | 57 (42.5%) | 22 (39.3%) | 35 (44.9%) |  |
 Male | 77 (57.5%) | 34 (60.7%) | 43 (55.1%) |  |
BMI |  |  |  | 0.672‡ |
 Mean (SD) | 21.0 (5.7) | 21.4 (5.3) | 20.7(6.2) |  |
Tumor size (cm) |  |  |  | 0.245‡ |
 Mean (SD) | 3.9 (2.0) | 4.1 (1.9) | 3.8 (2.1) |  |
Clinical T stage | Â | Â | Â | 0.170 |
 cT2 | 58 (43.3%) | 19 (33.9%) | 39 (50.0%) |  |
 cT3 | 57 (42.5%) | 27 (48.2%) | 30 (38.5%) |  |
 cT4 | 19 (14.2%) | 10 (17.9%) | 9 (11.5%) |  |
Clinical nodal status | Â | Â | Â | 0.601 |
 cN− | 70 (52.2%) | 31 (55.4%) | 39 (50.0%) |  |
 cN+ | 64 (47.8%) | 25 (44.6%) | 39 (50.0%) |  |
NACT regimen | Â | Â | Â | 0.625 |
 SOX | 114 (85.1%) | 49 (87.5%) | 65 (83.3%) |  |
 XELOX | 20 (14.9%) | 7 (12.5%) | 13 (16.7%) |  |
No. of NACT cycles | Â | Â | Â | 0.381 |
 2 | 15 (11.2%) | 8 (14.3%) | 7 (9.0%) |  |
 3 | 36 (26.9%) | 17 (30.4%) | 19 (24.4%) |  |
 4 | 83 (61.9%) | 31 (55.3%) | 52 (66.6%) |  |
Tumor location | Â | Â | Â | 0.860 |
 Upper third | 39 (29.1%) | 16 (28.6%) | 23 (29.5%) |  |
 Middle third | 44 (32.8%) | 20 (35.7%) | 24 (30.8%) |  |
 Lower third | 51 (38.1%) | 20 (35.7%) | 31 (39.7%) |  |
Type of resection | Â | Â | Â | 0.502 |
 Subtotal | 72 (53.7%) | 32 (57.1%) | 40 (51.3%) |  |
 Total | 62 (46.3%) | 24 (42.9%) | 38 (48.7%) |  |
Lauren type | Â | Â | Â | 0.138 |
 Intestinal | 86 (64.2%) | 40 (71.4%) | 46 (59.0%) |  |
 Diffuse/mixed | 48 (35.8%) | 16 (28.6%) | 32 (41.0%) |  |
Differentiation | Â | Â | Â | 0.934 |
 Well/moderate | 88 (65.7%) | 37 (66.1%) | 51 (65.4%) |  |
 Poor | 46 (34.3%) | 19 (33.9%) | 27 (34.6%) |  |
Signet ring cell | Â | Â | Â | 0.110 |
 No | 98 (73.1%) | 45 (80.4%) | 53 (67.9%) |  |
 Yes | 36 (26.9%) | 11 (19.6%) | 25 (32.1%) |  |
Pathological T stage | Â | Â | Â | 0.370 |
 ypT1 | 51 (38.1%) | 24 (42.9%) | 27 (34.6%) |  |
 ypT2 | 83 (61.9%) | 32 (57.1%) | 51 (65.4%) |  |
No. of lymph nodes | Â | Â | Â | Â |
 Mean (SD) | 29 (10) | 28 (9) | 30(12) | 0.332‡ |
Lymphovascular invasion | Â | Â | Â | 0.153 |
 No | 80 (59.7%) | 29 (51.8%) | 51 (65.4%) |  |
 Yes | 54 (40.3%) | 27 (48.2%) | 27 (34.6%) |  |
Pathological response (CAP) | Â | Â | Â | 0.316 |
 CAP 0 | 23 (17.2%) | 12 (21.4%) | 11 (14.1%) |  |
 CAP 1 | 30 (22.4%) | 11 (19.6%) | 19 (24.4%) |  |
 CAP 2 | 41 (30.6%) | 20 (35.7%) | 21 (26.9%) |  |
 CAP 3 | 40 (29.8%) | 13 (23.2%) | 27 (34.6%) |  |